Circulating Resolvin D1 and Resolvin E1 and carotid atherosclerotic burden in type 2 diabetes: a cross-sectional study

Failure to resolve inflammation may contribute to accelerated atherosclerosis in type 2 diabetes. We investigated whether circulating Resolvin D1 (RvD1) and Resolvin E1 (RvE1), measured by enzyme-linked immunosorbent assay (ELISA), are associated with carotid atherosclerotic burden and improve discrimination of prevalent carotid stenosis beyond carotid intima-media thickness (cIMT). In this single-center cross-sectional study, 139 adults with type 2 diabetes underwent carotid ultrasonography and serum resolvin measurement. The prespecified primary endpoint, ≥ 50% carotid stenosis, was present in 59 participants (42.4%). After adjustment for prespecified confounders, the association of ELISA-immunoreactive RvD1 with the primary endpoint was not statistically significant (prevalence ratio per 1-SD increment 0.72, 95% CI 0.49–1.03; p = 0.074). In exploratory secondary analyses, each 1-SD higher ELISA-immunoreactive RvD1 was associated with an adjusted 6.92%-point lower maximum stenosis (95% CI 2.79–11.05; p = 0.001) and with lower cIMT; ELISA-immunoreactive RvD1 also differed across plaque phenotypes in unadjusted comparisons ( p < 0.001), although phenotype overlapped with stenosis severity. Adding ELISA-immunoreactive RvD1 to the clinical model with cIMT increased the C-statistic by 0.010 (bootstrap 95% CI − 0.003 to 0.038). ELISA-immunoreactive RvE1 showed no statistically significant adjusted association with stenosis, cIMT, or plaque presence. These exploratory findings are hypothesis-generating and require confirmation with validated mass spectrometric measurements.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-21
DOI
https://doi.org/10.1038/s41598-026-81173-x
Primary Topic
Fatty Acid Research and Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Circulating Resolvin D1 and Resolvin E1 and carotid atherosclerotic burden in type 2 diabetes: a cross-sectional study

Gülsen Ersoy, Hakan Küçüksayan, Mahmut Çınar, İdris Kocatürk et al.
Scientific Reports
Fatty Acid Research and Health
article

Circulating Resolvin D1 and Resolvin E1 and carotid atherosclerotic burden in type 2 diabetes: a cross-sectional study

Gülsen Ersoy, Hakan Küçüksayan, Mahmut Çınar, İdris Kocatürk, Bahadır Reis, Çağatay ŞENOL, Sedat Gülten, Celal Demir, Tuba Uyanık, Yasemin Taşkıran
article en

Abstract

Failure to resolve inflammation may contribute to accelerated atherosclerosis in type 2 diabetes. We investigated whether circulating Resolvin D1 (RvD1) and Resolvin E1 (RvE1), measured by enzyme-linked immunosorbent assay (ELISA), are associated with carotid atherosclerotic burden and improve discrimination of prevalent carotid stenosis beyond carotid intima-media thickness (cIMT). In this single-center cross-sectional study, 139 adults with type 2 diabetes underwent carotid ultrasonography and serum resolvin measurement. The prespecified primary endpoint, ≥ 50% carotid stenosis, was present in 59 participants (42.4%). After adjustment for prespecified confounders, the association of ELISA-immunoreactive RvD1 with the primary endpoint was not statistically significant (prevalence ratio per 1-SD increment 0.72, 95% CI 0.49–1.03; p = 0.074). In exploratory secondary analyses, each 1-SD higher ELISA-immunoreactive RvD1 was associated with an adjusted 6.92%-point lower maximum stenosis (95% CI 2.79–11.05; p = 0.001) and with lower cIMT; ELISA-immunoreactive RvD1 also differed across plaque phenotypes in unadjusted comparisons ( p < 0.001), although phenotype overlapped with stenosis severity. Adding ELISA-immunoreactive RvD1 to the clinical model with cIMT increased the C-statistic by 0.010 (bootstrap 95% CI − 0.003 to 0.038). ELISA-immunoreactive RvE1 showed no statistically significant adjusted association with stenosis, cIMT, or plaque presence. These exploratory findings are hypothesis-generating and require confirmation with validated mass spectrometric measurements.

Scientific Reports
Kastamonu University (TR)
Fatty Acid Research and Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon